Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study.

Autor: Vasiliadou I; Guys Cancer Centre, Guy's and St. Thomas NHS Foundation Trust, London SE1 9RT, UK., Breik O; Department of Oncology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB, UK.; Department of Oral and Maxillofacial Surgery, Royal Brisbane and Women's Hospital, QLD 4029 Brisbane, Australia., Baker H; Department of Oncology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB, UK.; College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK., Leslie I; Head and Neck Unit, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK., Sim VR; Guys Cancer Centre, Guy's and St. Thomas NHS Foundation Trust, London SE1 9RT, UK., Hegarty G; Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Kent ME16 9QQ, UK., Michaelidou A; Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Kent ME16 9QQ, UK., Nathan K; Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Kent ME16 9QQ, UK., Hartley A; Department of Oncology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB, UK., Good J; Department of Oncology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB, UK., Sanghera P; Department of Oncology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB, UK., Fong C; Department of Oncology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB, UK., Urbano TG; Guys Cancer Centre, Guy's and St. Thomas NHS Foundation Trust, London SE1 9RT, UK., Lei M; Guys Cancer Centre, Guy's and St. Thomas NHS Foundation Trust, London SE1 9RT, UK., Petkar I; Guys Cancer Centre, Guy's and St. Thomas NHS Foundation Trust, London SE1 9RT, UK., Ferreira MR; Guys Cancer Centre, Guy's and St. Thomas NHS Foundation Trust, London SE1 9RT, UK., Nutting C; Head and Neck Unit, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK., Wong KH; Head and Neck Unit, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK., Newbold K; Head and Neck Unit, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK., Harrington K; Head and Neck Unit, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SW7 3RP, UK., Bhide S; Head and Neck Unit, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK., Kong A; Guys Cancer Centre, Guy's and St. Thomas NHS Foundation Trust, London SE1 9RT, UK.; Department of Oncology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2WB, UK.; College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.; Comprehensive Cancer Centre, King's College London, Guy's Campus, London SE1 1UL, UK.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2021 Mar 19; Vol. 13 (6). Date of Electronic Publication: 2021 Mar 19.
DOI: 10.3390/cancers13061413
Abstrakt: Nivolumab is an anti-PD-1 monoclonal antibody currently used as immunotherapy for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with evidence of disease progression after platinum-based chemotherapy. This study evaluates real-world safety and treatment outcomes of non-trial nivolumab use. A retrospective multicenter cohort study of patients with recurrent/metastatic HNSCC treated with nivolumab between January 2017 and March 2020 was performed. Overall, 123 patients were included. The median age was 64 years, the majority of patients were male (80.5%) and had a smoking history (69.9%). Primary outcomes included overall response rate (ORR) of 19.3%, median progression-free survival (PFS) of 3.9 months, 1-year PFS rate of 16.8%, a median overall survival (OS) of 6.5 months and 1-year OS rate of 28.6%. These results are comparable to the CHECKMATE-141 study. Of 27 patients who had PD-L1 status tested, positive PD-L1 status did not significantly affect PFS ( p = 0.86) or OS ( p = 0.84). Nivolumab was well tolerated with only 15.1% experiencing immune-related toxicities (IRT) and only 6.7% of patients stopping due to toxicity. The occurrence of IRT appeared to significantly affect PFS ( p = 0.01) but not OS ( p = 0.07). Nivolumab in recurrent/metastatic HNSCC is well tolerated and may be more efficacious in patients who develop IRT.
Databáze: MEDLINE
Externí odkaz: